PUBLICATIONS
Select 28 from 115
![](https://mauslab.com/wp-content/uploads/2024/07/Korell-STM-2024.webp)
Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics
Korell et al, Science Translational Medicine, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Frigault-Blood-2024.png)
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies
Frigault, Graham, Berger, et al, Blood, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Grauwet-JITC-2024.png)
Stealth transgenes enable CAR-T cells to evade host immune responses
Grauwet et al, Journal for Immunotherapy of Cancer, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Elsallab-TCT-2024.jpg)
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells
Elsallab et al, Transplantation and Cellular Therapy, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Choi-NEJM-2024.png)
Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma
Choi et al, New England Journal of Medicine, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Lee-et-al-CBCC-2024.png)
Optimization of a flow cytometry test for routine monitoring of B cell maturation antigen targeted CAR in peripheral blood
Lee et al, Cytometry B Clinical Cytometry, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Wehrli-CCR-2024.png)
Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma
Wehrli, Guinn, Birocchi et al, Clinical Cancer Research, 2024
![](https://mauslab.com/wp-content/uploads/2024/07/Larson-Nat-Comm-2023.png)
Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
Larson et al, Nature Communications, 2023
![](https://mauslab.com/wp-content/uploads/2024/07/Schmidts-2023.jpeg)
Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Ra2 are effective against heterogeneous glioblastoma
Schmidts et al, Neuro-Oncology Advances, 20203
![](https://mauslab.com/wp-content/uploads/2022/11/Nat-Med-289.png)
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
Haradhvala, Leick, Maurer, Gohil et al,
Nature Medicine 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-8.jpg)
Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault et al, Blood Advances 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-91.jpg)
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick et al, Cancer Cell 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-15.jpg)
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumors.
Larson et al, Nature 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-13.jpg)
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault et al, Blood 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-11.jpg)
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey et al, Blood Cancer Discovery 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-14.jpg)
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli et al, Journal for Immunotherapy of Cancer 2022
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-3.jpg)
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.
Jan et al, Science Translational Medicine 2021
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-16.jpg)
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sources.
Schmidts et al, Journal for Immunotherapy of Cancer 2020
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-5.jpg)
A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
Boroughs et al, Molecular Therapy 2020
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-17.jpg)
Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
Schmidts et al, Blood Advances 2019
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-1.jpg)
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj et al, Clinical Cancer Research 2019
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-2.jpg)
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
Choi et al, Nature Biotechnology 2019
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-4.jpg)
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.
Frigault et al, Blood 2019
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-7.jpg)
Chimeric antigen receptor costimulation domains modulate human regulatory T cell function.
Boroughs et al, JCI Insight 2019
![](https://mauslab.com/wp-content/uploads/2022/05/Maus-Lab-Publications-6.jpg)
Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas.
Scarfò et al, Blood 2018